

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

US PTO  
11/15/01  
JULY 3 1998  
09/987601

IN RE APPLICATION OF: Philippe MOULLIER et al

SERIAL NO: New U.S. Application

FILED: Herewith

FOR: BIOMATERIAL IMPLANT FOR THE EXPRESSION AND IN VIVO SECRETION OF A THERAPEUTIC SUBSTANCE

**INFORMATION DISCLOSURE/RELATED CASE STATEMENT UNDER 37 CFR 1.97**

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449 were mentioned in Parent Application, Serial No. 09/225,509 filed January 6, 1999.
- A check is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Registration No. 24,618

Daniel J. Pereira, Ph.D.  
Registration No. 45,518



**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 10/98)

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 216143US0DIV	SERIAL NO. New U.S. Application
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT		Philippe MOULLIER, et al.	
		FILING DATE Herewith		GROUP	
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS    SUB CLASS FILED IF APPROPRIATE
	AA	4,980,289	12/25/90	TEMIN, et al.	
	AB	5,906,817	5/99	MOULLIER et al	
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				
	AL				
	AM				
	AN				
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES    NO
	AO	WO 90 12603	11/01/90	WIPO	
	AP	WO 93 08850	05/13/93	WIPO	
	AQ	WO 93 07913	04/29/93	WIPO	
	AR	FR 2 460 657	01/30/81	FRANCE	
	AS	WO 92 07943	05/14/92	WIPO	
	AT	WO 91 10728	07/25/91	WIPO	
	AU	WO 90 02797	03/22/90	WIPO	
	AV	WO 92 15676	09/17/92	WIPO	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)					
	AW	A. SALVETTI, et al., "Retroviral vectors for the in vivo delivery of alpha-1-iduronidase and aryl-sulfatase b in human mucopolysaccharidoses type I and VI", <u>Journal of Cellular Biochemistry</u> , Vol. SUPO, No. 18A, Page 240, January 15, 1994; & Keystone Symposium on Gene Therapy, Copper Mountain, USA, January 15-January 22, 1994.			
	AX	P. MOULLIER, et al., "Implants of genetically modified skin fibroblasts for lysosomal enzyme delivery: studies in newborn mutant mice and in normal dogs", <u>Journal of Cellular Biochemistry</u> , Vol. SUPO, No. 18A, Page 239, January 15, 1994; & Keystone Symposium on Gene Therapy, Copper Mountain, USA, January 15-January 22, 1994.			
	AY	O. DANOS, et al., "Correction of lysosomal storage in beta-glucuronidase-deficient mice by genetically-modified cellular implants", <u>Journal of Cellular Biochemistry</u> , Vol. SUPPL, No. 17E, Page 225, March 29, 1993; & Keystone Symposium on Gene Therapy, Keystone, Colorado, USA, April 12- April 18, 1993.			
	AZ	O. DANOS, et al., "Reimplantation de cellules genetiquement modifiees dans des neo-organes vascularises", <u>Medecine-Sciences</u> , Vol. 9, No. 2, Pages 208-210, February 1993.			
Examiner					Date Considered
<p>*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. <u>216143US0DIV</u>		SERIAL NO. <u>New U.S. Application</u>	
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT		Philippe MOULLIER, et al.			
		FILING DATE <u>Herewith</u>		GROUP			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						
	BM						
	BN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
		BO EP 0 178 220	04/16/86	EUROPE	YES	NO	
	BP						
	BQ						
	BR						
	BS						
	BT						
	BU						
	BV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	BW	<u>P. MOULLIER, et al.</u> , "Continuous systemic secretion of a lysosomal enzyme by genetically modified mouse skin fibroblasts", <u>Transplantation</u> , Vol. 56, No. 2, Pages 427-432, August 1993.					
	BX	<u>P. MOULLIER, et al.</u> , "Organoid neovascular structure: effects of various matrix and angiogenic factors", <u>Journal of Cellular Biochemistry</u> , Vol. SUPPL, No. 15F, Page 242, April 1, 1991; & Meeting on FGF, endothelial cell growth factors and angiogenesis// 20th Annual Meeting of the Keystone Symposia on molecular and cellular biology, Keystone, USA, April 7, 1991.					
	BY	<u>J.C. GILBERT, et al.</u> , "Cell transplantation of genetically altered cells on biodegradable polymer scaffolds in syngeneic rats", <u>Transplantation</u> , Vol. 56, No. 2, Pages 423-427, August 1993.					
	BZ	<u>D. ST. LOUIS, et al.</u> , "An alternative approach to somatic cell gene therapy", <u>Proceedings of the National Academy of Sciences of USA</u> , Vol. 85, No. 9, Pages 3150-3154, May 1988, Washington, U.S.					
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## LIST OF REFERENCES CITED BY APPLICANT

ATTY DOCKET NO. 216143US0DIV	SERIAL NO. New U.S. Application
APPLICANT Philippe MOULLIER, et al.	
FILING DATE Herewith	GROUP

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

AAA	P. MOULLIER, et al., "Murine skin fibroblasts and bone marrow cells as targets for in vivo transfer and expression of the human beta-glucuronidase cDNA", <u>Journal of Cellular Biochemistry</u> , Vol. SUPPL, No. 16F, Page 62, April 3, 1992; & Keystone symposium on gene transfer, replacement and augmentation, Copper Mountain, Colorado, USA, April 3- April 9, 1992.
AAB	J. A. THOMPSON, et al., "Site-directed neovessel formation in vivo", <u>Science</u> , Vol. 241, No. 4871, Pages 1349- 1352, September 9, 1988, Lancaster, PA, U.S.
AAC	Gomez-Narvarro et al. "Gene therapy of cancer.", <u>Eur. J. Cancer</u> , Vol. 35 (6): 867-885.
AAD	Ledley, F., "Pharmaceutical Approach to Somatic Gene Therapy." <u>Pharmaceutical Res.</u> , Vol. 13 (11): 1595-1614
AAE	
AAF	
AAG	
AAH	
AAI	
AAJ	
AAK	
AAL	
AAM	
AAN	
AAO	
AAP	
AAQ	

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.